163521-12-8 Usage
Description
Different sources of media describe the Description of 163521-12-8 differently. You can refer to the following data:
1. Vilazodone is a kind of serotonergic antidepressant developed by Merck KGaA Company. It is a novel compound with high affinity and selectivity for the 5-hydroxytrptamine (5-HT) transporter and 5-HT (1A) receptors. It is indicated for the treatment of major depressive disorder (MDD). It is can be used as an alternative drugs for other kind of antidepressant classes drugs that can’t be tolerated by patients. As a selective serotonin reuptake inhibitor, vilazodone can prevent the serotonin from re-entering into cell bodies, therefore making it remain longer inside the synapse. Moreover, it has a high selectivity for the serotonin-1A receptor, taking effect as a partial agonist that can simulate the production of serotonin. These effects result in increased serotonin in the synaptic cleft. This effect is related to the antidepressant effect of vilazodone in vivo.
2. In January 2011, the U.S. FDA approved vilazodone for the treatment of
major depressive disorder (MDD).
Vilazodone is a novel antidepressant agent that combines potent serotonin reuptake inhibition (IC50=0.2 nM) with high affinity for 5-HT1A receptors (IC50=0.5 nM)and partial 5-HT1A receptor agonist functional activity. Vilazodone has good
selectivity over other monoamine receptors and is efficacious in preclinical
models of depression in rats and mice. Vilazodone is an
indolylbutylpiperazine derivative that has been prepared by coupling of an
indolylbutyl chloride or tosylate with 5-(piperazin-1-yl)benzofuran-2-
carboxamide or the corresponding ester. The cyanoindole portion of
vilazodone is important for conferring high affinity for both the serotonin
transporter and the 5-HT1A receptor. Para-substitution on the phenyl
group attached to the piperidine moiety reduces affinity for dopamine
receptors, while the carboxamide group provides improved pharmacokinetic
properties.
References
https://www.drugbank.ca/drugs/DB06684
https://en.wikipedia.org/wiki/Vilazodone
http://www.rxlist.com/viibryd-drug/indications-dosage.htm
Chemical Properties
Light Yellow Solid
Originator
Merck KGaA (Germany)
Uses
Different sources of media describe the Uses of 163521-12-8 differently. You can refer to the following data:
1. It is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.
2. Labelled analogue of Vilazodone
3. An inhibitor of ST and activator of SR-1A
Definition
ChEBI: A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder.
Brand name
Viibryd
Check Digit Verification of cas no
The CAS Registry Mumber 163521-12-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,5,2 and 1 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 163521-12:
(8*1)+(7*6)+(6*3)+(5*5)+(4*2)+(3*1)+(2*1)+(1*2)=108
108 % 10 = 8
So 163521-12-8 is a valid CAS Registry Number.
163521-12-8Relevant articles and documents
Preparation method of vilazodone
-
Paragraph 0033-0052, (2021/02/06)
The invention relates to a preparation method of vilazodone. The preparation method comprises the steps of by using a compound 1 and a compound 2 as raw materials, carrying out one-step reaction underthe condition that trifluoroacetic acid is used as a solvent to obtain a compound I, namely the vilazodone. Compared with the prior art, the method has the advantages of short reaction route, easy post-treatment, high yield, cheap and easily available reagents used in the reaction, convenient operation, simple post-treatment, low cost, small environmental pollution, and suitableness for industrial production of vilazodone.
Preparation method of vilazodone hydrochloride
-
Page/Page column 8-11, (2019/02/04)
The invention discloses a preparation method of vilazodone hydrochloride. The preparation method comprises the following steps: (1) in the presence of ammonium hydroxide or ammonium hydroxide and N-methylpyrrolidone, enabling 5-(1-piperazinyl)-benzofuran-2-ethyl formate hydrochloride to be subjected to ammonolysis reaction to obtain 5-(1-piperazinyl)-benzofuran-2-formamide; (2) in the presence ofalkali, enabling the 5-(1-piperazinyl)-benzofuran-2-formamide and 3-(4-chlorobutyl) indole-5-formonitrile to be subjected to nucleophilic substitution reaction to obtain a crude product of vilazodone,wherein the alkali is mixed alkali of sodium iodide, N,N-diisopropylethylamine and triethylamine or 1,8-diazabicycloundec-7-ene; (3) refining the crude product of vilazodone to obtain a refined product of vilazodone; and (4) enabling the refined product of vilazodone to be subjected to salt-forming reaction to obtain the vilazodone hydrochloride. By virtue of the ammonolysis reaction and the nucleophilic substitution reaction, the yield is higher, and the purity is higher; and the yield of the vilazodone hydrochloride is increased.
A PROCESS FOR PREPARATION OF 2-BENZOFURANCARBOXAMIDE, 5-[4-[4-(5CYANO-1H-INDOL-3-YL)BUTYL]-1-PIPERAZINYL] FREE BASE AND ITS HYDROCHLORIDE SALT
-
, (2016/09/22)
The present invention describes an advantageous, economically viable process for preparing 5-[4-[4-(5-Cyanoindole-3-yl)butyl]Piperazine-1-yl]benzofuran-2-carboxamide free base (Formula-I) and its hydrochloride salt. The instant invention also describes process for preparing 2-benzofurancarboxamide, 5-[4-[4-(5cyano-1H-indol-3-yl)butyl]-1- piperazinyl]intermediates.
